Advertisement

Linear IgA Bullous Dermatosis

  • Julia A. Curtis
  • John J. ZoneEmail author
Chapter

Abstract

Linear IgA bullous dermatosis (LABD) is a unique autoimmune blistering disease which can present both in children and adults. There are various clinical presentations of the disease which can involve both cutaneous and mucosal tissues. LABD has been reported to be associated with medications, ulcerative colitis, and malignancies. This chapter will discuss the diagnosis, current therapies, and possible treatment algorithms for managing LABD patients.

Keywords

Linear IgA bullous disease Systemic steroids Dapsone Azathioprine Mycophenolate mofetil Cyclophosphamide Methotrexate Rituximab Intravenous Immunoglobulin 

References

  1. 1.
    Chorzelski T, Jablonska S. Evolving concept of IgA linear dermatosis. Semin Dermatol. 1988;7(3):225–32.PubMedGoogle Scholar
  2. 2.
    Egan CA, Zone JJ. Linear IgA bullous dermatosis. Int J Dermatol. 1999;38(11):818–27.CrossRefPubMedGoogle Scholar
  3. 3.
    Guide SV, Marinkovich MP. Linear IgA bullous dermatosis. Clin Dermatol. 2001;19(6):719–27.CrossRefPubMedGoogle Scholar
  4. 4.
    Antiga E, Caproni M, Fabbri P. Linear immunoglobulin a bullous dermatosis: need for an agreement on diagnostic criteria. Dermatology. 2013;226(4):329–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Horiguchi Y, Ikoma A, Sakai R, Masatsugu A, Ohta M, Hashimoto T. Linear IgA dermatosis: report of an infantile case and analysis of 213 cases in Japan. J Dermatol. 2008;35(11):737–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Sakaguchi M, Bito T, Oda Y, et al. Three cases of linear IgA/IgG bullous dermatosis showing IgA and IgG reactivity with multiple antigens, particularly laminin-332. JAMA Dermatol. 2013;149(11):1308–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol. 2012;66(6):988–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol. 1996;106(4):734–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Zone JJ, Taylor TB, Kadunce DP, Meyer LJ. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest. 1990;85(3):812–20.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Ishii N, Ohyama B, Yamaguchi Z, Hashimoto T. IgA autoantibodies against the NC16a domain of BP180 but not 120-kDa LAD-1 detected in a patient with linear IgA disease. Br J Dermatol. 2008;158(5):1151–3.CrossRefPubMedGoogle Scholar
  11. 11.
    Tsuchisaka A, Ohara K, Ishii N, Nguyen NT, Marinkovich MP, Hashimoto T. Type VII collagen is the major autoantigen for sublamina densa-type linear IgA bullous dermatosis. J Invest Dermatol. 2015;135:626–9.Google Scholar
  12. 12.
    Gluth MB, Witman PM, Thompson DM. Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis. Int J Pediatr Otorhinolaryngol. 2004;68(7):965–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Kelly SE, Frith PA, Millard PR, Wojnarowska F, Black MM. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol. 1988;119(2):161–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Chanal J, Ingen-Housz-Oro S, Ortonne N, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013;169(5):1041–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Paige DG, Leonard JN, Wojnarowska F, Fry L. Linear IgA disease and ulcerative colitis. Br J Dermatol. 1997;136(5):779–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Caldarola G, Annese V, Bossa F, Pellicano R. Linear IgA bullous dermatosis and ulcerative colitis treated by proctocolectomy. Eur J Dermatol EJD. 2009;19(6):651.PubMedGoogle Scholar
  17. 17.
    Walker SL, Banerjee P, Harland CC, Black MM. Remission of linear IgA disease associated with ulcerative colitis following panproclocolectomy. Br J Dermatol. 2000;143(6):1341–2.CrossRefPubMedGoogle Scholar
  18. 18.
    Dippel E, Orfanos CE, Zouboulis C. Linear IgA dermatosis presenting with erythema annulare centrifugum lesions: report of three cases in adults. J Eur Acad Dermatol Venereol JEADV. 2001;15(2):167–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Adamic M, Potocnik M, Pavlovic MD. Linear IgA bullous dermatosis in a patient with advanced pancreatic carcinoma. Clin Exp Dermatol. 2008;33(4):503–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Gantzer A, Bouaziz JD, Valeyrie-Allanore L, Ingen-Housz-Oro S, Ortonne N, Bagot M. Acute linear IgA bullous dermatosis with circulating IgA monoclonal antibody associated with Hodgkin’s disease. Ann Dermatol Venereol. 2010;137(12):819–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Hollo P, Preisz K, Nemes L, Biro J, Karpati S, Horvath A. Linear IgA dermatosis associated with chronic clonal myeloproliferative disease. Int J Dermatol. 2003;42(2):143–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Nassar D, Gabillot-Carre M, Ortonne N, et al. Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma. Arch Dermatol. 2009;145(3):342–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Usmani N, Baxter KF, Child JA, Sheehan-Dare R. Linear IgA disease in association with chronic lymphocytic leukaemia. Br J Dermatol. 2004;151(3):710–1.CrossRefPubMedGoogle Scholar
  24. 24.
    Cooke N, Jenkinson H, Wojnarowska F, McKenna K, Alderdice J. Coexistence of psoriasis and linear IgA disease in a patient with recent herpes zoster infection. Clin Exp Dermatol. 2005;30(6):643–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Takagi Y, Sawada S, Yamauchi M, Amagai M, Niimura M. Coexistence of psoriasis and linear IgA bullous dermatosis. Br J Dermatol. 2000;142(3):513–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Salmhofer W, Soyer HP, Wolf P, Fodinger D, Hodl S, Kerl H. UV light-induced linear IgA dermatosis. J Am Acad Dermatol. 2004;50(1):109–15.CrossRefPubMedGoogle Scholar
  27. 27.
    Chorzelski TP, Jablonska S, Maciejowska E. Linear IgA bullous dermatosis of adults. Clin Dermatol. 1991;9(3):383–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Mintz EM, Morel KD. Clinical features, diagnosis, and pathogenesis of chronic bullous disease of childhood. Dermatol Clin. 2011;29(3):459–62. ix.CrossRefPubMedGoogle Scholar
  29. 29.
    Navi D, Michael DJ, Fazel N. Drug-induced linear IgA bullous dermatosis. Dermatol Online J. 2006;12(5):12.PubMedGoogle Scholar
  30. 30.
    Ng SY, Venning VV. Management of linear IgA disease. Dermatol Clin. 2011;29(4):629–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Wojnarowska F, Kirtschig G, Khumalo N. Treatment of subepidermal immunobullous diseases. Clin Dermatol. 2001;19(6):768–77.CrossRefPubMedGoogle Scholar
  32. 32.
    Venning VA. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Dermatol Clin. 2011;29(3):453–8. ix.CrossRefPubMedGoogle Scholar
  33. 33.
    Ang P, Goh BK, Giam YC. Case reports of linear IgA bullous dermatosis of childhood. Ann Acad Med Singapore. 1999;28(6):849–54.PubMedGoogle Scholar
  34. 34.
    Willsteed E, Lee M, Wong LC, Cooper A. Sulfasalazine and dermatitis herpetiformis. Australas J Dermatol. 2005;46(2):101–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Ang P, Tay YK. Treatment of linear IgA bullous dermatosis of childhood with colchicine. Pediatr Dermatol. 1999;16(1):50–2.CrossRefPubMedGoogle Scholar
  36. 36.
    Kenani N, Mebazaa A, Denguezli M, et al. Childhood linear IgA bullous dermatosis in Tunisia. Pediatr Dermatol. 2009;26(1):28–33.CrossRefPubMedGoogle Scholar
  37. 37.
    Banodkar DD, al-Suwaid AR. Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood. Int J Dermatol. 1997;36(3):213–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Tay YK, Ang P. Treatment of linear IgA bullous dermatosis of childhood with colchicine: in reply. Pediatr Dermatol. 2000;17(2):157.CrossRefPubMedGoogle Scholar
  39. 39.
    Zeharia A, Hodak E, Mukamel M, Danziger Y, Mimouni M. Successful treatment of chronic bullous dermatosis of childhood with colchicine. J Am Acad Dermatol. 1994;30(4):660–1.CrossRefPubMedGoogle Scholar
  40. 40.
    Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28(6):998–1000.CrossRefPubMedGoogle Scholar
  41. 41.
    Peoples D, Fivenson DP. Linear IgA bullous dermatosis: successful treatment with tetracycline and nicotinamide. J Am Acad Dermatol. 1992;26(3 Pt 2):498–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Yomada M, Komai A, Hashimato T. Sublamina densa-type linear IgA bullous dermatosis successfully treated with oral tetracycline and niacianamide. Br J Dermatol. 1999;141(3):608–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Alajlan A, Al-Khawajah M, Al-Sheikh O, et al. Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin. J Am Acad Dermatol. 2006;54(4):652–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Farrant P, Darley C, Carmichael A. Is erythromycin an effective treatment for chronic bullous disease of childhood? a national survey of members of the British Society for Paediatric Dermatology. Pediatr Dermatol. 2008;25(4):479–82.CrossRefPubMedGoogle Scholar
  45. 45.
    Mervic L, Dragos V, Pavlovic MD. Linear IgA bullous dermatosis of childhood: successful treatment with miocamycin and topical corticosteroid. Clin Exp Dermatol. 2009;34(7):e391–2.CrossRefPubMedGoogle Scholar
  46. 46.
    Monia K, Aida K, Amel K, Ines Z, Becima F, Ridha KM. Linear IgA bullous dermatosis in tunisian children: 31 cases. Indian J Dermatol. 2011;56(2):153–9.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Siegfried EC, Sirawan S. Chronic bullous disease of childhood: successful treatment with dicloxacillin. J Am Acad Dermatol. 1998;39(5 Pt 1):797–800.CrossRefPubMedGoogle Scholar
  48. 48.
    Cooper SM, Powell J, Wojnarowska F. Linear IgA disease: successful treatment with erythromycin. Clin Exp Dermatol. 2002;27(8):677–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Farley-Li J, Mancini AJ. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol. 2003;139(9):1121–4.CrossRefPubMedGoogle Scholar
  50. 50.
    Glaser R, Sticherlin M. Successful treatment of linear IgA bullous dermatosis with mycophenolate mofetil. Acta Derm Venereol. 2002;82(4):308–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Goebeler M, Seitz C, Rose C, et al. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol. 2003;149(4):912–4.CrossRefPubMedGoogle Scholar
  52. 52.
    Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. J Am Acad Dermatol. 1999;40(3):485–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Kroiss MM, Vogt T, Landthaler M, Stolz W. High-dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol. 2000;142(3):582.CrossRefPubMedGoogle Scholar
  54. 54.
    Letko E, Bhol K, Foster CS, Ahmed AR. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology. 2000;107(8):1524–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Lewis MA, Yaqoob NA, Emanuel C, Potts AJ. Successful treatment of oral linear IgA disease using mycophenolate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(4):483–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Marzano AV, Ramoni S, Spinelli D, Alessi E, Berti E. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium. J Dermatolog Treat. 2008;19(6):364–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Segura S, Iranzo P, Martinez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol. 2007;56(6):960–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Talhari C, Mahnke N, Ruzicka T, Megahed M. Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent. Clin Exp Dermatol. 2005;30(3):297–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc. 2005;80(1):41–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Young HS, Coulson IH. Linear IgA disease: successful treatment with cyclosporin. Br J Dermatol. 2000;143(1):204–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Cauza K, Hinterhuber G, Sterniczky B, et al. Unusual clinical manifestation of linear IgA dermatosis: a report of two cases. J Am Acad Dermatol. 2004;51(2 Suppl):S112–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Anstey AV, Wakelin S, Reynolds NJ; British Association of Dermatologists Therapy; Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004;151(6):1123–32.Google Scholar
  63. 63.
    Belgi G, Friedmann PS. Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea. Clin Exp Dermatol. 2002;27(7):546–54.CrossRefPubMedGoogle Scholar
  64. 64.
    Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol. 1995;32(1):114–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Smith JR, Kupa A, Coster DJ. Linear IgA disease. Aust N Z J Ophthalmol. 1999;27(6):443–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Wolverton SE. Comprehensive dermatologic drug therapy. Philadelphia: Saunders; 2001.Google Scholar
  67. 67.
    Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol. 1996;104 Suppl 1:3–9.PubMedGoogle Scholar
  68. 68.
    Lozinski A, Baum S, Sagi L, Volkov A, Trau H, Barzilai A. Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders. Harefuah. 2012;151(10):562–5. 606.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations